BTK and B-cell chronic lymphocytic leukemia: A non-randomized study with few data in subjects receiving BTK-, PI3K- or BCL-2-inhibitors pre-, peri- and/or post-transplant reported transplant outcomes similar to those reported in transplant recipients receiving conventional CLL drugs, but it is impossible to comment critically [20].